Islam Hassan: For Patients, for Caregivers, and for the Future of Oncology
Islam Hassan, Global Head of Development (Neuro-Oncology) at Servier Pharmaceuticals, shared a post by Servier Pharmaceuticals, adding:
“One year ago today, the FDA approved the first and only targeted therapy for Grade 2 IDH-mutant glioma. This milestone was so important for patients who had waited more than 20 years for a therapy like this.
Developing it was a collaborative effort—and one I’m proud to have been part of alongside an extraordinary team! In the year since, the therapy has been made available to patients across the US, bringing an option to those facing a relentless disease. Milestones like this one remind me why I do this work. And why we must keep pushing forward…
For patients, for caregivers, and for the future of oncology.”
Quoting Servier Pharmaceuticals‘s post:
“One year ago, Servier brought the first and only FDA–approved targeted therapy for Grade 2 IDH-mutant glioma to patients in the U.S., marking the first significant treatment breakthrough for this relentless condition in over two decades.
Today, our commitment remains stronger than ever as we continue to drive progress forward for patients and families affected by glioma and other IDH-mutated cancers. Learn more about our ongoing efforts here.”
More posts featuring Islam Hassan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023